Key Points
- Insider purchase: Humana insider Sanjay Shetty bought 810 shares on Feb. 23 at an average of $185.21 for a total of $150,020.10, increasing his position by 7.47% to 11,657 shares (about $2.16M); the trade was disclosed in an SEC Form 4 filing.
- Company performance & market action: Humana beat quarterly EPS estimates (reported -$3.96 vs. -$4.01) with revenue up 11.3%, set FY2026 guidance at $9.00 EPS, its stock traded up ~3.1% to $181.50, and the company declared a $0.885 quarterly dividend (annual $3.54, ~2.0% yield).
Humana Inc. (NYSE:HUM - Get Free Report) insider Sanjay Shetty bought 810 shares of the company's stock in a transaction dated Monday, February 23rd. The shares were acquired at an average cost of $185.21 per share, for a total transaction of $150,020.10. Following the completion of the transaction, the insider owned 11,657 shares of the company's stock, valued at approximately $2,158,992.97. The trade was a 7.47% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Humana Stock Up 3.1%
NYSE HUM traded up $5.44 during mid-day trading on Thursday, reaching $181.50. 556,783 shares of the company's stock traded hands, compared to its average volume of 2,239,369. The company has a current ratio of 2.00, a quick ratio of 2.00 and a debt-to-equity ratio of 0.70. The company has a fifty day simple moving average of $232.20 and a 200-day simple moving average of $257.02. The company has a market cap of $21.89 billion, a price-to-earnings ratio of 18.46, a P/E/G ratio of 1.87 and a beta of 0.44. Humana Inc. has a 1-year low of $169.61 and a 1-year high of $315.35.
Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings data on Wednesday, February 11th. The insurance provider reported ($3.96) EPS for the quarter, beating analysts' consensus estimates of ($4.01) by $0.05. The firm had revenue of $32.64 billion for the quarter, compared to the consensus estimate of $32.08 billion. Humana had a net margin of 0.92% and a return on equity of 11.43%. The firm's revenue was up 11.3% compared to the same quarter last year. During the same period in the prior year, the firm posted ($2.16) EPS. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. As a group, equities research analysts expect that Humana Inc. will post 16.47 EPS for the current year.
Humana Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Friday, April 24th. Investors of record on Friday, March 27th will be paid a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a yield of 2.0%. The ex-dividend date is Friday, March 27th. Humana's dividend payout ratio (DPR) is 36.05%.
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the business. Capital International Investors raised its position in Humana by 113.9% during the fourth quarter. Capital International Investors now owns 5,818,008 shares of the insurance provider's stock valued at $1,490,239,000 after acquiring an additional 3,097,571 shares in the last quarter. Massachusetts Financial Services Co. MA raised its holdings in shares of Humana by 273.2% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,488,261 shares of the insurance provider's stock valued at $907,541,000 after purchasing an additional 2,553,509 shares in the last quarter. Norges Bank acquired a new stake in shares of Humana in the 4th quarter valued at $456,632,000. Wellington Management Group LLP increased its position in Humana by 4,481.7% during the fourth quarter. Wellington Management Group LLP now owns 1,196,502 shares of the insurance provider's stock worth $306,460,000 after buying an additional 1,170,387 shares during the last quarter. Finally, Franklin Resources Inc. raised its holdings in Humana by 914.5% during the fourth quarter. Franklin Resources Inc. now owns 1,255,665 shares of the insurance provider's stock valued at $321,613,000 after buying an additional 1,131,893 shares in the last quarter. Institutional investors and hedge funds own 92.38% of the company's stock.
Wall Street Analyst Weigh In
Several equities research analysts recently issued reports on HUM shares. Oppenheimer set a $250.00 price target on Humana in a research report on Thursday, February 12th. Leerink Partners dropped their target price on shares of Humana from $267.00 to $185.00 and set a "market perform" rating on the stock in a report on Thursday, February 12th. Guggenheim decreased their price target on shares of Humana from $312.00 to $252.00 and set a "buy" rating for the company in a report on Thursday, February 12th. Weiss Ratings reiterated a "sell (d+)" rating on shares of Humana in a research note on Thursday, January 22nd. Finally, Zacks Research cut shares of Humana from a "hold" rating to a "strong sell" rating in a report on Thursday, January 1st. Seven research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and four have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $225.48.
Read Our Latest Stock Analysis on Humana
Humana Company Profile
(
Get Free Report)
Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana's products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.
In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
